Welcome to our dedicated page for EASTMAN CHEMICAL CO SEC filings (Ticker: EMN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on EASTMAN CHEMICAL CO's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into EASTMAN CHEMICAL CO's regulatory disclosures and financial reporting.
Eastman Chemical executive Julie A. McAlindon reported an equity award of company stock. On February 11, 2026, she acquired 7,280 shares of Eastman Chemical common stock at a price of $0 per share, reported as a grant, award, or other acquisition.
The footnote explains this reflects the determination of performance shares earned for the three-year 2023–2025 performance period, meaning the award was tied to multi‑year performance goals. After this grant, McAlindon directly beneficially owned 20,011 common shares, and indirectly beneficially owned an additional 887 shares through an ESOP.
Caveness Michelle H reported acquisition or exercise transactions in a Form 4 filing for EMN. The filing lists transactions totaling 1,937 shares. Following the reported transactions, holdings were 8,183 shares.
Eastman Chemical executive Brian Travis Smith acquired 10,589 shares of common stock on February 11, 2026 through a performance award. The shares were granted at a price of $0 per share following the determination of performance shares earned for the 2023–2025 period.
After this award, Smith directly beneficially owns 27,321 shares of Eastman Chemical common stock.
Eastman Chemical senior vice president Adrian James Holt received an equity award linked to company performance. On 02/11/2026, Holt acquired 2,297 shares of Eastman Chemical common stock at a price of $0 per share. These shares were granted following the determination of performance shares earned for the three-year 2023–2025 performance period, and are held as direct beneficial ownership.
Eastman Chemical Company reports 2025 full-year results and outlines its strategy as a global specialty materials company. Sales revenue reached $8.8 billion, with EBIT of $776 million, net earnings attributable to Eastman of $474 million, and diluted EPS of $4.10. Net cash from operating activities was $970 million.
The company emphasizes an innovation-driven growth model, focusing on specialty polymers, films, additives, intermediates, and fibers across four segments. It highlights molecular recycling and “Renew” branded products, with its polyester molecular recycling facility generating about 2.5 times more output than 2024. Around 55% of 2025 sales came from outside the United States and Canada.
Eastman Chemical CEO and Board Chair Mark J. Costa reported an insider equity transaction involving company stock on February 4, 2026. He exercised 48,649 employee stock options at an exercise price of $65.16 per share, receiving the same number of Eastman Chemical common shares.
A portion of these shares, 43,638, was withheld by Eastman Chemical to cover the option exercise price and tax withholding obligations in a net exercise, which the filing states does not represent a sale by Costa. After these transactions, Costa directly owned 458,997 shares of common stock, with an additional 3,231 shares held indirectly through an ESOP.
Eastman Chemical Company’s EVP and CFO, William Thomas McLain Jr., reported an option-related share transaction. On 02/04/2026 he exercised employee stock options for 3,013 shares of common stock at an exercise price of $65.16 per share.
To cover the option exercise price and tax withholding in a “net exercise,” 2,636 shares were withheld by Eastman Chemical and not sold on the market. After these transactions, he directly beneficially owned 53,901 shares of Eastman Chemical common stock.
A shareholder of EMN has filed a Rule 144 notice to sell 6,016 common shares through Fidelity Brokerage Services LLC on or about 02/04/2026, to be sold on the NYSE with an aggregate market value of $475,011.96.
The shares come from restricted stock that vested as compensation on 02/19/2021, 10/15/2022, and 02/15/2023, in amounts of 2,249, 1,040, and 2,727 shares. Shares outstanding were 114,069,800 at the time of the notice; this is a baseline figure, not the amount being sold.
Eastman Chemical Company filed a current report to furnish its financial results for the fourth quarter of 2025. The company states that it publicly released these results on January 29, 2026, and has attached the full earnings press release as an exhibit.
The earnings release is provided as Exhibit 99.01 and is incorporated by reference, but is designated as “furnished” rather than “filed” under securities law, which affects how it is treated for certain legal liabilities and future regulatory filings.
Eastman Chemical Company reported an equity award to executive officer Stephen G. Crawford, EVP, Technology Projects. On 01/02/2026, he received 34,193 restricted stock units (RSUs), each representing a contingent right to receive one share of Eastman Chemical common stock. These RSUs were reported as derivative securities beneficially owned directly.
The RSUs carry a conversion price of $0 and are scheduled to vest and pay out in unrestricted shares of common stock on February 2, 2027, subject to Mr. Crawford’s continued employment. After this grant, he beneficially owns 34,193 derivative securities in the form of RSUs tied to Eastman Chemical common stock.